HRAS and bladder transitional cell carcinoma: However, at the time of our investigation DNMT3A, FBXW7, HRAS, RAF1 and TOP1 are not yet found as genomic markers in BLCA related clinical trials and we are the first to report them as potential candidates for marker-driven therapy testing13.